A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

  • Ingham, Matthew (PI)

Project: Research project

Project Details

StatusActive
Effective start/end date1/1/19 → …

Funding

  • American Society of Clinical Oncology: US$200,000.00

ASJC Scopus Subject Areas

  • Cancer Research
  • Medicine(all)